期刊文献+

TACE联合缓释化疗粒子(5-Fu)治疗原发性肝癌的临床研究 被引量:4

A Clinical Study on TACE combined with Slow-released 5-fluorouracil for Hepatocellular Carcinoma
下载PDF
导出
摘要 目的评价肝动脉化疗栓塞术(TACE)、肝动脉化疗栓塞联合5-FU缓释粒子(TACE+5-FU)的综合介入治疗方法治疗肝癌的疗效,为临床合理化治疗方案的确定提供参考与帮助。方法 192例原发性肝癌分成TACE组(A组)及TACE+缓释粒子(5-FU)组(B组),对不同治疗手段疗效进行比较分析。结果治疗后A、B组1年生存率分别为69.02%、83.54%,2年生存率分别为26.54%、40.5%,3年生存率分别为7.9%、17.72%,A、B组术后1年复发率分别为60.33%、49.28%,术后2年复发率分别为76.59%、61.24%。结论 TACE+缓释粒子(5-FU) Objective To evaluate the clinical efficacy of transcatheter arterial chemoembolization(TACE) combined with slow-released 5-fluorouracil in the comprehensive Interventional treatment of hepatocellular carcinoma(HCC) to find the better therapeutic program for clinical use.Methods 192 patients with primary hepatocellular carcinoma were divided into two groups.TACE was Group A,group B was TACE+5-FU.Results The 1-year survival rates of 2 group were 69.02%,83.54% and 2-year survival rates of 2group were 26.54%,40.5% and 3-year survival rates of 2 group were 7.9%,17.72% respectively.The post-treatment recurrent rates of group A and B were 60.33%,49.28% for one year,76.59%,61.24% for two years respectively.Conclusion For primary hepatocellular carcinoma,TACE with slow-released 5-fluorouracil is a better method than TACE only.
出处 《当代医学》 2010年第17期302-304,共3页 Contemporary Medicine
关键词 原发性肝癌:介入 5-氟尿嘧啶缓释粒子 经导管动脉化疗栓塞 slow-released 5-fluorouracil hepatocellular carcinoma Interventional treatments transcatheter arterial chemoembolization
  • 引文网络
  • 相关文献

参考文献6

  • 1Choi B I Kim HC,Han JK et aI.Therapeutic effect of transcatheter oilychemoembolizatiion therpy for emcapsulated nodular hepatocellular carcinoma: CT and pathlotogic findings [J]. Radiology, 1992m182 (3) : 709-713.
  • 2Staunton M Dodd JD,Mocormick PA,et aI,Finding evidencebased answers to practical question in radiology:which patients with inoperable hapatocellular carcinoma will survive longer aftertransarterial chemoembolizatiion Radiology, 2005 237 : 404-413.
  • 3Okuda K,Ohtsuk T,Obata H et aI.Natural history of hepatocellular carcinoma and prognosis in relation to treatment;study of 850 patients. Cancer 1985 56.9 8-928.
  • 4Okadas. Transcatheter arterial embolization for advanced hepatocellular carcinoma: The controversy continues. Hepatology , 1998 27:1743-1744.
  • 5吴美艳.彩色多普勒对肝癌肝动脉栓塞术前后肝血流改变的探讨[J].中国超声医学杂志,1999,15(6):420-421. 被引量:36
  • 6周剑寅,叶社房,王效民.控缓释制剂治疗肝癌新进展[J].国外医学(肿瘤学分册),2005,32(12):933-936. 被引量:3

二级参考文献22

  • 1李开艳,张青萍,胡道予.彩色多普勒对肝癌肝动脉栓塞前后门静脉血流动力学的研究[J].中国超声医学杂志,1993,9(5):319-321. 被引量:16
  • 2汪阳,胡国栋.肝节段动脉栓塞治疗原发性肝癌[J].中华放射学杂志,1996,30(2):85-89. 被引量:57
  • 3Kan Z,Radiology,1993年,187卷,621页
  • 4Abe S, Otsuki M. Styrene maleic acid neocarzinostatin treatment for hepatocellular carcinoma. Curr Med Chem Anti-Canc Agents,2002,2(6) :715-726.
  • 5Kishimoto S, Miyazawa K, Fukushima S, et al. In vitro antitumor activity,intracellular accumulation, and DNA adduct formation of cis-[ ( (1R,2R)-1,2-cyclohexanediamine-n, n') bis ( myristato ) ] platinum(Ⅱ) suspended in lipiodol. Jpn J Cancer Res, 2000,91 (1) :99-104.
  • 6Okusaka T, Okada S, Nakanishi T, et al. Phase Ⅱ trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11555 ) in patients with hepatocellular carcinoma. Invest New Drugs,2004,22(2) :169-176.
  • 7Pourgholami MH, Akhter J, Finlay IG, et al. 1,25-dihydroxyvitamin D3 dissolved in lipiodol produces a sustained antiproliferative effect in the human hepatoblastoma cell line HepG2. Anticancer Res, 2000,20(2A) :723-727.
  • 8Morris DL, Jourdan JL, Finlay I, et al. Hepatic intra-arterial injection of 1,25-dihydroxyvitamin D3 in lipiodol: Pilot study in patients with hepatocellular carcinoma. Int J Oncol, 2002,21 (4) :901-906.
  • 9Mok TS, Kanekal S, Lin XR, et al. Pharmacokinetic study of intralesional cisplatin for the treatment of hepatocellular carcinoma. Cancer,2000,91 (12) :2369-2377.
  • 10Leung TW, Yu S, Johnson PJ, et al. Phase Ⅱ study of the efficacy and safety of cisplatin-epinephrine injectable gel administered to patients with unresectable hepatocellular carcinoma. J Clin Oncol,2003,21 (4) :652-658.

共引文献37

同被引文献87

引证文献4

二级引证文献22

;
使用帮助 返回顶部